|
Oct 12
|
Praxis Precision Medicines, Inc (PRAX): A Small-Cap Leader in Biopharmaceuticals
|
|
Sep 26
|
Praxis Precision Medicines presents on ulixacaltamide Essential3 program at the Movement Disorders Society 2024 International Congress
|
|
Aug 13
|
Praxis Precision Medicines, Inc. (PRAX) Reports Q2 Loss, Lags Revenue Estimates
|
|
Aug 13
|
Praxis Precision Medicines Provides Corporate Update and Reports Second Quarter 2024 Financial Results
|
|
Aug 7
|
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know
|
|
Jun 21
|
Praxis Precision Medicines (PRAX) Surges 6.4%: Is This an Indication of Further Gains?
|
|
Jun 20
|
Jazz Dives — But Key Rival Praxis Surges — On Essential Tremor Drug Failure
|
|
May 30
|
This Is Why Praxis Precision Medicines, Inc.'s (NASDAQ:PRAX) CEO Compensation Looks Appropriate
|
|
May 17
|
Praxis Precision Medicines to Participate in Upcoming Investor Conferences
|
|
May 14
|
We're Hopeful That Praxis Precision Medicines (NASDAQ:PRAX) Will Use Its Cash Wisely
|
|
May 13
|
Praxis Precision Medicines Provides Corporate Update and Reports First Quarter 2024 Financial Results
|
|
May 10
|
Praxis Precision Medicines to Report First Quarter 2024 Financial Results on Monday, May 13, 2024
|
|
May 2
|
Wall Street Analysts See a 144.74% Upside in Praxis Precision Medicines (PRAX): Can the Stock Really Move This High?
|
|
Apr 12
|
Praxis Precision Medicines to Present on Ulixacaltamide at the American Academy of Neurology 2024 Annual Meeting
|
|
Apr 11
|
Praxis Precision Medicines (PRAX) Upgraded to Buy: Here's Why
|
|
Apr 5
|
Praxis Precision Medicines to Participate in Upcoming April Conferences
|
|
Mar 29
|
Health Care Roundup: Market Talk
|
|
Mar 28
|
Biotech Stock Roundup: PRAX, VKTX Up on Study Results & MRNA, REGN Give Updates
|
|
Mar 28
|
Praxis Precision Medicines, Inc. Announces Pricing of $200 Million Public Offering
|
|
Mar 27
|
Praxis (PRAX) Surges on Positive Epilepsy Study Results
|